hsa-mir-210 |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
High |
Gastric Cancer |
cell line (BGC823) |
hsa-mir-210 |
Ceritinib |
57379345 |
NSC776422 |
approved |
resistant |
|
High |
Non-Small Cell Lung Cancer |
cell line (H3122, H2228) |
hsa-mir-210 |
Dabrafenib |
44462760 |
NSC764134 |
approved |
resistant |
|
|
|
cell line (A375) |
hsa-mir-210 |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
|
|
cell line (W1) |
hsa-mir-210 |
Androstenedione |
6128 |
NSC9563 |
|
sensitive |
|
|
|
cell line (MCF-7) |
hsa-mir-210 |
Androstenedione+Letrozole |
|
|
|
sensitive |
|
|
|
cell line (MCF-7) |
hsa-mir-210 |
Tamoxifen |
2733525 |
NSC180973 |
approved |
resistant |
|
|
|
tissue (ER-positive breast cancer) |
hsa-mir-210 |
Fluorouracil |
3385 |
NSC19893 |
approved |
sensitive |
|
|
|
cell line (OE19) |
hsa-mir-210 |
Ceritinib |
57379345 |
NSC776422 |
approved |
resistant |
|
|
|
cell line (H3122) |
hsa-mir-210 |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (BGC-823) |
hsa-miR-210-3p |
(E)-1-[3,5-bis[(dimethylamino)methyl]-4-hydroxyphenyl]-3-phenylprop-2-en-1-one |
6374691 |
NSC677784 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
(e)-3-chloro-3-(4-methoxyphenyl)-2-(4-nitrophenyl)prop-2-enal |
5387396 |
NSC623175 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
[(E)-(1-chloro-2-methylpropylidene)amino] N-anilinocarbamate |
5494354 |
NSC682841 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
[(E)-1-chloropropylideneamino] N-[2-(trifluoromethoxy)phenyl]carbamate |
5466266 |
NSC682836 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
[2-[(e)-(carbamothioylhydrazono)methyl]-6-methoxy-phenoxy]-hydroxy-copper; 2-(2-pyridyl)pyridine |
135484845 |
NSC638302 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
1-(4-ethoxyphenyl)-3-(2-methyl-5-propan-2-ylphenyl)urea |
240168 |
NSC46213 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
1-(4-nitrophenyl)-3-(2-pyridyl)thiourea |
3005383 |
NSC695329 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
1-(naphthalen-1-ylmethyl)-4-[1-(naphthalen-1-ylmethyl)piperidin-4-yl]piperidine |
364095 |
NSC669995 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
1-[2-(4-nitrophenyl)-2-oxoethyl]-4-pentylpyridin-1-ium bromide |
24181037 |
NSC4290 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
11-(3-methoxyphenyl)-2,12,15-triazapentacyclo[11.7.1.03,8.09,21.014,19]henicosa-1,3,5,7,9,11,13(21),14(19),15,17-decaen-20-one |
54608964 |
NSC697747 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
17-acetyl-9,14-dihydroxy-16-methyl-15-(4-methylphenyl)-15-azatetracyclo[8.7.0.01,14.03,8]heptadeca-3,5,7,9,12,16-hexaene-2,11-dione |
405612 |
NSC722982 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
1h-benz[g]indol-5-ol, 2-phenyl |
371327 |
NSC645431 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
2-[[4-anilino-5-[8-[4-anilino-5-[(1-hydroxynaphthalen-2-yl)oxymethyl]-1,2,4-triazol-3-yl]octyl]-1,2,4-triazol-3-yl]methoxy]naphthalen-1-ol |
394049 |
NSC697167 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
2-[9-[(7-oxocyclohepta-1,3,5-trien-1-yl)amino]nonylamino]cyclohepta-2,4,6-trien-1-one |
358331 |
NSC618296 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
2-amino-5,8-dihydroxy-1,4-naphthoquinone |
377209 |
NSC658441 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
2-bromo-4-(5-fluoro-1,3-benzothiazol-2-yl)aniline |
399248 |
NSC709925 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
2-hydroxy-5-({(e)-[(10-hydroxyacridin-9(10h)-ylidene)methyl]diazenyl}sulfonyl)benzoic acid |
363212 |
NSC627890 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
3'-chloro-3-nitro-o-salicylotoluidide |
332278 |
NSC328477 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
3-((4-(methylthio)phenoxy)methyl)-2-oxiranol |
366923 |
NSC636087 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-(2-phenylethylamino)naphthalene-1,2-dione |
367789 |
NSC637731 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-[(E)-2-piperidin-1-ylethenyl]benzo[g]quinoline-5,10-dione |
5781544 |
NSC642968 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-[(r)-[(2s,5r)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-methoxyphenyl)methyl]-n-pentan-3-ylbenzamide;hydrochloride |
5471112 |
NSC708822 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-[2-(methylamino)-1-methylsulfanylethyl]benzene-1,2-diol |
412349 |
NSC39215 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-[4-(4-sulfinobutyldisulfanyl)butyldisulfanyl]butane-1-sulfinic acid |
361262 |
NSC624205 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-acetamido-n-[(e)-(2,4-dichlorophenyl)methylideneamino]-2-methoxybenzamide |
9572428 |
NSC716142 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
4-aminodithiolane-4-carboxylic acid |
269217 |
NSC109825 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4-hydroxy-3-[1-(1-hydroxy-3,4-dioxonaphthalen-2-yl)-3-phenylpropyl]naphthalene-1,2-dione |
272651 |
NSC117274 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4,4-dimethylspiro[1,3,2-oxazaphospholidin-2-ium-2,2'-3h-1,3,2-benzoxazaphosphol-2-ium]-5-one |
6330525 |
NSC351866 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4b-hydroxy-10,10-dimethoxy-9ah-indeno[1,2-a]inden-9-one |
363252 |
NSC628000 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
4h,7h-furo[2',3',4':4,5]naphth[2,1-e][1,3]oxazin-4-one, 8-(4-chlorophenyl)-8,9-dihydro- |
373969 |
NSC651001 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
5,6,7-trimethoxy-N-(4H-pyrazolo[1,5-a]indol-2-yl)-1H-indole-2-carboxamide |
404173 |
NSC720326 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
6-(3-chloropropyl)-3-nitroindeno[1,2-c]isoquinoline-5,11-dione |
17755848 |
NSC731154 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
6-benzyloxyhexanal |
389877 |
NSC686505 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
7-[(E)-2-(1,6-dimethylquinolin-1-ium-2-yl)ethenyl]-5-methylquinolin-8-ol |
135483953 |
NSC86371 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
7-[(naphthalen-1-ylamino)(phenyl)methyl]quinolin-8-ol |
256754 |
NSC84092 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
7-chloro-6-n-(2-fluoroethylamino)-5,8-quinolinedione |
379079 |
NSC663286 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
7-o,8-o-isopropylidene iriomoteolide 3a |
24808220 |
NSC753164 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
9h-quino[4,3,2-de][1,10]phenanthrolin-9-one, 2-phenyl- |
4567749 |
NSC686553 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Acetyltrophanthidin |
261075 |
NSC92954 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Adenosine, 2-bromo-2'-deoxy- |
334838 |
NSC341936 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Asimicinone |
393461 |
NSC695394 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Benzo[b]naphtho[2,3-d]furan-6,11-dione, 4-chloro-3-hydroxy |
371025 |
NSC644902 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Benzo[g]pteridine-2,4(3h,10h)-dione, 10-(2,4-dimethylphenyl)-3-methyl- |
363228 |
NSC627974 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Benzo[g]pteridine-2,4(3h,10h)-dione, 10-(4-chlorophenyl)-3,7,8-trimethyl- |
363246 |
NSC627992 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Benzo[g]pteridine-2,4(3h,10h)-dione, 3-methyl-10-[3-(methylthio)phenyl]- |
363242 |
NSC627988 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Benzo[g]quinoxaline-5,10-dione, 5,10-dihydro-2,3-dimethyl- |
353644 |
NSC602617 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Celcot rm |
67277 |
NSC37168 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Cytarabine |
6253 |
NSC287459 |
approved |
resistant |
|
|
|
|
hsa-miR-210-3p |
Destruxin a |
122810 |
NSC361126 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Di-p-tolyliodinium bromide |
54601177 |
NSC8985 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Diethoxybis(1,4-naphthochinone-2-olato)titanium(iv) |
368297 |
NSC638842 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Dihydrorotenone |
243725 |
NSC53866 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Diisopropoxybis(1,4-naphthochinone-2-olato)titanium(iv) |
368058 |
NSC638383 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Discorhabdin i |
135409047 |
NSC656206 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Dpbq |
364074 |
NSC629713 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Ethyl 6-chloro-4-phenyl-2-(piperazin-1-ylmethyl)quinoline-3-carboxylate |
369623 |
NSC641536 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Ethyl 6-hydroxy-4-(4-methoxyphenyl)-6-methyl-3-oxo-2-phenyl-1,4,5,7-tetrahydroindazole-5-carboxylate |
392845 |
NSC693857 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Gnmlngdfmleynr-uhfffaoysa-n |
402862 |
NSC717147 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
Gw612286x |
9822610 |
NSC756278 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
Gw811761x |
6539382 |
NSC756375 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
Herbimycin |
6436247 |
NSC305978 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Hypothemycin |
5458809 |
NSC354462 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Indole-2,3-dione, 5-methyl-, 3-[(o-nitrophenyl)hydrazone] |
3632950 |
NSC117915 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
J3.572.907k |
396709 |
NSC703318 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Methyl 10-acetyl-3-(4-methylphenyl)sulfonyl-9-(2-methylprop-1-enyl)-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaene-11-carboxylate |
|
NSC621968 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Methyl 8-[(4-chlorophenyl)carbamoyl]naphthalene-1-carboxylate |
364289 |
NSC630307 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
N-(2-morpholin-4-ylethyl)-5-nitroquinolin-4-amine;hydrochloride |
372042 |
NSC646859 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
N-(3-chloro-1,4-dioxonaphthalen-2-yl)-4-naphthalen-2-yl-2,4-dioxo-3-(3-oxo-1H-2-benzofuran-1-yl)butanamide |
369463 |
NSC641233 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
N-(3,5-dicyano-2-(4-methylphenyl)-6-oxo-4-phenyl-1(6h)-pyridinyl)-4-methylbenzenesulfonamide |
390286 |
NSC687578 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
N-[(1E)-1-(1-hydroxypyridin-2-ylidene)ethyl]iminoazepane-1-carbothioamide |
5369124 |
NSC351075 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
N-[1,1,1,3,3,3-hexafluoro-2-(4-fluoroanilino)propan-2-yl]butanamide |
389152 |
NSC684836 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Naphtho[2,3-d]-1,3-dioxepin-6,11-dione, 4-methyl- |
|
NSC626868 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Naphtho[2,3-d]oxazole-4,9-dione, 2-(1,1-dimethylethyl)- |
370622 |
NSC643915 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Niosh/br9826000 |
359483 |
NSC620462 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
NSC619321 |
|
NSC619321 |
|
sensitive |
|
|
|
|
hsa-miR-210-3p |
NSC621321 |
|
NSC621321 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
NSC631451 |
|
NSC631451 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
NSC634766 |
|
NSC634766 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
NSC635414 |
|
NSC635414 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Pentyl 6-(chloromethyl)-2-oxo-2h-chromene-3-carboxylate |
402498 |
NSC716524 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Pmp (van) |
72508 |
NSC1906 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Scillirosidin, glycoside |
222160 |
NSC7534 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Sesbanimide |
163490 |
NSC355461 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Snc 80 |
123924 |
NSC707484 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Streptovaricin b |
135443622 |
NSC156215 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Tetratert-butyl 8,11-dimethoxytricyclo[4.3.3.01,6]dodeca-7,10-diene-7,9,10,12-tetracarboxylate |
362411 |
NSC626176 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Tolonium chloride |
7083 |
NSC36758 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Z48861686 |
4784054 |
NSC745813 |
|
resistant |
|
|
|
|
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-miR-210-3p |
Temozolomide |
5394 |
NSC362856 |
approved |
resistant |
|
High |
Glioblastoma |
cell line (U251MG, U251R, U87MG, M059K, M059J) |
hsa-miR-210-3p |
Imatinib |
5291 |
NSC743414 |
approved |
resistant |
|
High |
Myelogenous Leukemia |
cell line (MYL) |
hsa-miR-210-3p |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
High |
Colon Cancer |
cell line (HT-29) |
hsa-miR-210-3p |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
High |
Colon Cancer |
cell line (HT-29) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
High |
Ehrlich Ascites Tumor |
cell line (EHR2,P6, P12, P36, P72, EHR2/1.3) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
resistant |
|
High |
Ehrlich Ascites Tumor |
cell line (EHR2,P6, P12, P36, P72, EHR2/1.3) |
hsa-miR-210-3p |
Trastuzumab |
|
|
|
resistant |
|
Low |
Breast Cancer |
tissue and cell line (BT-474, BTR65) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Gastric Cancer |
cell line (SGC7901) |
hsa-miR-210-3p |
Vincristine |
5978 |
|
approved |
sensitive |
|
High |
Gastric Cancer |
cell line (SGC7901) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
High |
Gastric Cancer |
cell line (SGC7901) |
hsa-miR-210-3p |
Fluorouracil |
3385 |
NSC19893 |
approved |
sensitive |
|
High |
Gastric Cancer |
cell line (SGC7901) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
Low |
Cervical Cancer |
tissue and cell line (SiHa, Cask) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
High |
Laryngeal Cancer |
cell line (Hep2) |
hsa-miR-210-3p |
Fluorouracil + Oxaliplatin |
|
|
|
resistant |
|
High |
Colorectal Cancer |
tissue |
hsa-miR-210-3p |
Docetaxel |
148124 |
NSC628503 |
approved |
resistant |
|
High |
Prostate Cancer |
cell line (DU-145) |
hsa-miR-210-3p |
Asparaginate |
5460875 |
|
|
sensitive |
|
Low |
Pediatric Acute Lymphoblastic Leukemia |
Reh cells |
hsa-miR-210-3p |
Dexamethasone |
5743 |
NSC34521 |
approved |
sensitive |
|
Low |
Pediatric Acute Lymphoblastic Leukemia |
Reh cells |
hsa-miR-210-3p |
Daunorubicin |
30323 |
NSC82151 |
approved |
sensitive |
|
Low |
Pediatric Acute Lymphoblastic Leukemia |
Reh cells |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
High |
Pancreatic Cancer |
cell line (PANC-1) |
hsa-miR-210-3p |
Fluorouracil |
3385 |
NSC19893 |
approved |
resistant |
|
High |
Pancreatic Cancer |
cell line (PANC-1) |
hsa-miR-210-3p |
Fluorouracil |
3385 |
NSC19893 |
approved |
sensitive |
|
High |
Esophageal Adenocarcinoma |
cell line (OE19) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
resistant |
|
High |
Hepatocellular Carcinoma |
tissue and cell line (HepG2) |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
sensitive |
|
High |
Pancreatic Cancer |
cell line (SW1990) |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
High |
Pancreatic Cancer |
cell line (SW1990) |
hsa-miR-210-3p |
Taxane |
9548828 |
|
|
sensitive |
|
High |
Prostate Cancer |
cell line (PC-3, PR20) |
hsa-miR-210-3p |
Taxane |
9548828 |
|
|
sensitive |
|
High |
Prostate Cancer |
cell line (PC-3, PR70) |
hsa-miR-210-3p |
Dexamethasone |
5743 |
NSC34521 |
approved |
sensitive |
|
High |
Myeloma |
cell line (MM1R, MM1S) |
hsa-miR-210-3p |
Platinum |
23939 |
|
|
sensitive |
|
High |
Ovarian Cancer |
tissue |
hsa-miR-210-3p |
Daunorubicin |
30323 |
NSC82151 |
approved |
sensitive |
|
High |
Acute Myeloid Leukemia |
cell line (U-937, KG-1) |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
Low |
Pancreatic Ductal Adenocarcinoma |
cell line (MIA-PaCa-2) |
hsa-miR-210-3p |
Trametinib |
11707110 |
NSC758246 |
approved |
sensitive |
|
Low |
Melanoma |
cell line (MML-1) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
High |
Ovarian Cancer |
cell line (SKOV3) |
hsa-miR-210-3p |
Tamoxifen |
2733525 |
NSC180973 |
approved |
resistant |
|
Low |
Breast Cancer |
cell line (TAMR4, TAMR8) |
hsa-miR-210-3p |
Aromatase Inhibitor |
|
|
|
sensitive |
|
Low |
Breast Cancer |
cell line (MCF-7) |
hsa-miR-210-3p |
Epirubicin |
41867 |
NSC256942 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MDA-MB-231) |
hsa-miR-210-3p |
Docetaxel |
148124 |
NSC628503 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MDA-MB-231) |
hsa-miR-210-3p |
Vinorelbine |
44424639 |
|
approved |
resistant |
|
High |
Breast Cancer |
cell line (MDA-MB-231) |
hsa-miR-210-3p |
1'-Acetoxychavicol acetate |
119104 |
NSC711510 |
|
resistant |
|
Low |
Cervical Cancer |
cell line (Ca Ski, SiHa) |
hsa-miR-210-3p |
Dabrafenib |
44462760 |
NSC764134 |
approved |
sensitive |
|
High |
Melanoma |
cell line (A375, IGR37, 501Mel) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
High |
Melanoma |
cell line (A375, IGR37, 501Mel) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (A549) |
hsa-miR-210-3p |
Imatinib |
5291 |
NSC743414 |
approved |
sensitive |
|
High |
Chronic Myelogenous Leukemia |
cell line (K562) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
Low |
Renal Cell Cancer |
cell line (Caki-2) |
hsa-miR-210-3p |
Vinblastine |
442111 |
NSC90636 |
approved |
sensitive |
|
Low |
Renal Cell Cancer |
cell line (Caki-2) |
hsa-miR-210-3p |
Fulvestrant |
17756771 |
NSC719276 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-miR-210-3p |
Ceritinib |
57379345 |
NSC776422 |
approved |
resistant |
|
High |
Non-Small Cell Lung Cancer |
cell line (H3122, H2228) |
hsa-miR-210-3p |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
High |
Colorectal Cancer |
cell line (LS174T) |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
Low |
Cholangiocarcinoma |
cell line (KKU-213, KKU-055, KKU-100) |
hsa-miR-210-3p |
Docetaxel |
148124 |
NSC628503 |
approved |
resistant |
|
Low |
Breast Cancer |
tissue |
hsa-miR-210-3p |
Palbociclib |
5330286 |
NSC758247 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (T47D) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
High |
Ovarian Cancer |
cell line (SKOV3) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
Low |
Ovarian Cancer |
cell line (SKOV3) |
hsa-miR-210-3p |
Cetuximab + Folfox(Fluorouracil + Leucovorin + Oxaliplatin) |
|
|
|
sensitive |
|
High |
Metastatic Colorectal Cancer |
tissue |
hsa-miR-210-3p |
Fluorouracil |
3385 |
NSC19893 |
approved |
sensitive |
|
Low |
Colorectal Cancer |
cell line (HT-29) |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
Low |
Pancreatic Cancer |
cell line (BXPC-3) |
hsa-miR-210-3p |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
High |
Colorectal Adenocarcinoma |
cell line (HT-29) |
hsa-miR-210-3p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
Low |
Pancreatic Cancer |
cell line (PANC-1) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
Low |
Oral Cancer |
cell line (SAS, HSC-3, HSC-4) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
High |
Endometrial Serous Carcinoma |
cell line (USPC1) |
hsa-miR-210-3p |
Imatinib |
5291 |
NSC743414 |
approved |
sensitive |
|
Low |
Chronic Myelogenous Leukemia |
tissue |
hsa-miR-210-3p |
Dabrafenib |
44462760 |
NSC764134 |
approved |
resistant |
|
High |
Melanoma |
cell line (A375) |
hsa-miR-210-3p |
Sunitinib |
5329102 |
NSC750690 |
approved |
resistant |
|
Low |
Renal Cell Cancer |
tissue |
hsa-miR-210-3p |
Temozolomide |
5394 |
NSC362856 |
approved |
resistant |
|
Low |
Glioma |
cell line (U87) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Hypopharyngeal Cancer |
cell line (FaDu) |
hsa-miR-210-3p |
Platinum |
23939 |
|
|
resistant |
|
High |
High-Grade Serous Ovarian Cancer |
tissue |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
Low |
Breast Cancer |
cell line (MCF-7) |
hsa-miR-210-3p |
Sorafenib |
216239 |
NSC747971 |
approved |
resistant |
|
High |
Hepatocellular Carcinoma |
cell line (PLC/PRF5-R1, PLC/PRF5-R2, PLC/PRF5) |
hsa-miR-210-3p |
Gefitinib |
123631 |
NSC715055 |
approved |
sensitive |
|
|
|
cell line (HCC827) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
|
|
cell line (A375) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (CAL-27) (total RNA) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (CAL-27) (mitochondrial RNA) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
|
|
cell line (451Lu) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (A549) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
|
|
cell line (SKVO3ip1) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
|
|
cell line (HeyA8) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
|
|
cell line (LM17) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
resistant |
|
|
|
cell line (LM16) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
|
|
cell line (LM11) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
resistant |
|
|
|
cell line (LM43) |
hsa-miR-210-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
resistant |
|
|
|
cell line (LM47) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
|
|
cell line (HS578T) |
hsa-miR-210-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
resistant |
|
|
|
cell line (BAS) |
hsa-miR-210-3p |
Tamoxifen+Fulvestrant |
|
|
|
sensitive |
|
|
|
cell line (LCC9) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (CIS) |
hsa-miR-210-3p |
Exemestane |
60198 |
NSC713563 |
approved |
resistant |
|
|
|
cell line (MCF-7) |
hsa-miR-210-3p |
Testosterone |
6013 |
NSC9700 |
approved |
resistant |
|
|
|
cell line (MCF-7) |
hsa-miR-210-3p |
Testosterone+Exemestane |
|
|
|
resistant |
|
|
|
cell line (MCF-7) |
hsa-miR-210-3p |
Testosterone+Letrozole |
|
|
|
resistant |
|
|
|
cell line (MCF-7) |
hsa-miR-210-3p |
Testosterone+Anastrozole |
|
|
|
resistant |
|
|
|
cell line (MCF-7) |
hsa-miR-210-3p |
Testosterone+Tamoxifen |
|
|
|
resistant |
|
|
|
cell line (MCF-7) |
hsa-miR-210-3p |
Osimertinib |
71496458 |
NSC779217 |
approved |
sensitive |
|
|
|
cell line (H1975) |
hsa-miR-210-3p |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
|
|
cell line (HT29) |
hsa-miR-210-3p |
Fluorouracil |
3385 |
NSC19893 |
approved |
resistant |
|
|
|
cell line (KM12C) (72 h) |
hsa-miR-210-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (RPMI2650) |
hsa-miR-210-3p |
Sunitinib |
5329102 |
NSC750690 |
approved |
resistant |
|
|
|
tissue (CardA) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
|
|
cell line (SKOV3) |
hsa-miR-210-3p |
Platinum |
23939 |
|
|
resistant |
|
|
|
tissue (non-small cell lung cancer) |
hsa-miR-210-3p |
Tamoxifen |
2733525 |
NSC180973 |
approved |
resistant |
|
|
|
cell line (TamR4) |
hsa-miR-210-3p |
Tamoxifen |
2733525 |
NSC180973 |
approved |
resistant |
|
|
|
cell line (TamR8) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
|
|
cell line (PC3PR20) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
|
|
cell line (PC3PR200) |
hsa-miR-210-3p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|